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Abstract
Purpose Renal cell carcinomas (RCC) frequently express
the gastrin-releasing peptide receptor (GRP-R). Gastrin-
releasing peptide (GRP) stimulates tumor cell proliferation
and neoangiogenesis. Tumor-associated macrophages (TAM)
comprise an important cellular component of these tumors. We
analyzed the GRP/GRP-R network in clear cell RCC (ccRCC)
and non-clear cell RCC (non-ccRCC) with special regard to its
expression by macrophages, tumor cells and microvessels.
Methods Gastrin-releasing peptide and GRP-R expression
in 17 ccRCC and 9 non-ccRCC were analyzed by RT-PCR,
immunohistochemistry and double immunoXuorescence
staining.
Results Tumor-associated macrophages expressed GRP
and GRP receptor in ccRCC. Tumor cells and microvessels
showed low to intermediate GRP-R expression in nearly all
cases. In 12 ccRCC tumor epithelia also expressed low
levels of GRP. Microvascular GRP expression was found
in nine cases of ccRCC. For non-RCC, the expression of
GRP and GRP receptor expression pattern was similar.
Conclusions Tumor-associated macrophages are the main
source of GRP in RCC. GRP receptor on TAM, tumor epi-
thelia and microvessels might be a molecular base of a
GRP/GRP receptor network, potentially acting as a para-
crine/autocrine modulator of TAM recruitment, tumor
growth and neoangiogenesis.
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Introduction
Gastrin-releasing peptide (GRP) is the human analog of the
amphibian tetradecapeptide bombesin. McDonald et al. [1]
was the Wrst to describe GRP in the gastrointestinal tract of
mammals. GRP, originally named for its ability to stimulate
the release of gastrin, modulates the secretion of a variety
of gastrointestinal hormones and aVects pancreatic secre-
tion, intestinal transit, muscle contractility, metabolism and
behavior [2]. The expression of GRP is not only restricted
to the gastrointestinal tract and it is also widely distributed
in the central nervous system.
GRP interacts with four diVerent G-protein coupled
receptors: the GRP receptor (subtype I), the neuromedin-B
receptor, the Bombesin receptor (subtype 3), and a novel
subtype 4 that has been identiWed in frogs. In humans, GRP
binds to the GRP receptor with high aYnity and to the
subtype 3 receptor with low aYnity.
GRP has been identiWed as an important growth factor
not only for neuroendocrine malignancies, such as medullary
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336 World J Urol (2010) 28:335–341thyroid carcinomas [3], small cell lung carcinomas [4] and
neuroblastomas [5], but also for carcinomas of the breast
[6], colon [7], prostate [8] and rat pancreatic cancer [9]. The
growth of renal cell carcinoma (RCC) has been linked to
the presence of GRP and its receptor by Pansky et al. [10]
who stimulated the growth of various RCC cell lines with
GRP. Reubi et al. [11] identiWed the GRP receptor on
tumor epithelia in human RCC specimens using a radioac-
tive ligand. We have shown recently that the GRP receptor
is not only found on tumor epithelia, but also expressed in
microvessels [12]. We likewise demonstrated that the
microvascular GRP receptor is potentially relevant for neo-
angiogenesis in RCC, because microvessel formation is
inhibited by the GRP receptor antagonist RC-3095 in an
animal model of a dorsal skinfold chamber.
Malignant tumors comprise up to 50% stromal cells of
which monocytes/macrophages are a quantitative and
functional important subpopulation. The tumor microenvi-
ronment and hypoxia induce a diVerentiation of tumor-
associated macrophages (TAM) into a phenotype with
depressed cytotoxicity [13–15] which may enhance growth
and spread of tumor cells [16–18].
Neuropeptides, e.g. GRP, signiWcantly modulate the
function of macrophages. The GRP receptor has been found
on macrophages, and GRP has an eVect on macrophage
function such as displayed by an alteration of adhesion,
migration and phagocytosis [19, 20]. Interestingly, GRP
expression in macrophages has been reported only under
inXammatory conditions, such as chronic bronchitis and
lung inXammation and Wbrosis [21, 22]. In inXammation,
the Wndings of simultaneous peptide and receptor expres-
sion suggest an autocrine loop in the macrophage environ-
ment that may be important for the macrophage/epithelium
interaction.
In the present study, we conWrm the presence of GRP
and GRP receptor mRNA transcripts in tumor tissue of
human clear cell RCC (ccRCC) and non-clear cell RCC
(non-ccRCC). Moreover, as novel Wnding, we co-localize
an expression of GRP and GRP-R in TAM and also in
microvessels. We conclude that the GRP/GRP receptor sys-
tem in RCC and TAM may represent a link between growth
regulation in the tumor and local immune response.
Materials and methods
Patients and tumors
Seventeen ccRCC and nine non-ccRCC were freshly
obtained at the time of surgery from the urological depart-
ment of our institution. Approval of the ethics committee
had been obtained before initiation of the study. Histopa-
thological data are summarized in Table 1.
Immunohistochemistry and immunoXuorescence
Tissues were Wxed in HOPE™ (Hepes–glutamic acid
buVer-mediated organic solvent protection eVect) solu-
tion (DCS Diagnostic Systems, Hamburg, Germany) and
embedded in paraYn according to the manufacturer’s
instructions. Tissue sections (3 m) were mounted on
glass slides, de-paraYnized, rehydrated and subjected to
immunohistochemistry. Sections were incubated with a
polyclonal rabbit anti-gastrin-releasing peptide antibody
(1:50 dilution, Dako, Hamburg Germany) or polyclonal
rabbit anti-gastrin-releasing peptide receptor (GRP-R)
antibody (1:200 dilution; kindly donated by Dr. Battey,
NIDCD, Rockville, MD) at room temperature for 2 h.
After several washing steps, the sections were subse-
quently incubated with Envision™ peroxidase (Dako)
for 30 min. Signals were detected with diaminobenzi-
dine as substrate (Dako). Finally, sections were counter-
stained with hematoxylin, dehydrated with ethanol and
xylene and covered with cover slips.
Immunohistochemical staining for GRP and its receptor
was semiquantitatively analyzed by means of an immuno-
reaction score: 0, no staining; 1 staining <10% of cells; 2
10–50% of cells stained; 3 >50% of cells stained.
For double immunoXuorescence analysis, sections were
incubated with a mixture of anti-GRP (1:25) and CD68
(1:3,000, Dako Clone KP-1) at 4°C overnight. Anti-CD 68
antibody was detected with an anti-mouse Cy3 conjugate
(1:500 dilution for 1 h at RT). Subsequently, the sections
were incubated with anti-rabbit Envision-Peroxidase
(Dako) for 1 h at RT and incubated with tyramide-FITC to
detect GRP (tyramid signal ampliWcation, PerkinElmer/
NEN, Rodgau, Germany). Finally, sections were mounted
with Xuoromount (Dako). ImmunoXuorescence stainings
were visualized by means of an Axiophot Xuorescence
microscope (Zeiss, Göttingen, Germany) and a Xuores-
cence camera (Fview, Olympus, Hamburg, Germany).
mRNA expression analysis
ParaYn sections of HOPE-Wxed tissue were cut under
RNAse-free conditions and transferred to reaction tubes.
The sections were de-paraYnized with three changes of
isopropanol at 60°C for at least 90 min. The sections were
washed with absolute ethanol, air dried and lysed in lysis
buVer applying the RNAeasy mini kit (Qiagen, Hilden,
Germany), and RNA was extracted according to the manu-
facturer’s instructions. The quality and quantity of isolated
RNA were tested in an automated capillary electrophoresis
system (Agilent BioAnalyzer 2100; Agilent Technologies,
Waldbronn, Germany). A maximum of 500 ng of total
RNA was reverse transcribed using random hexamer prim-
ers (Invitrogen, Karlsruhe, Germany) and Omniscript™123
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RNA/l) at 37°C for 60 min according to the manufac-
turers instructions.
A 25 ng of cDNA was subjected to PCR analysis in a
total volume of 20 l using Hotstart Mastermix (Qiagen)
and primer pairs with conditions as summarized in Table 2.
Porphobilinogen deaminase was used as a house-keeping
gene which is constantly expressed in renal carcinomas.
PCR products were separated on a 1.5% agarose gel,
stained with ethidium bromide and analyzed on a UV trans-
illuminator. The used primers are given in Table 2.
Statistics
For the analysis of the immunohistological staining, the one-
way ANOVA with Dunnett’s post test was performed using
GraphPad Prism version 4.00 for Windows, GraphPad
Software, San Diego CA USA, http://www.graphpad.com.
Table 1 Synopsis of clinicopathological data and expression analysis of ccRCC and non-ccRCC
pap papillary carcinoma, sarc sarcomatoid carcinoma. db Duct Bellini carcinoma, n.a. not applicable
CcRCC Grade pTNM Tumor cells Stromal cells RNA
Macrophages Vessels
GRP GRP-R GRP GRP-R GRP GRP-R GRP GRP-R PBGD
Case
1 G1 pT1b, Nx, Mx 1 1 1 n.a. 0 3 2 2 2
2 G1 pT1a, Nx, Mx 1 2 0 1 1 1 0 0 3
3 G1 pT1b, Nx, Mx 0 2 3 2 1 2 2 3 2
4 G2 pT2, Nx, M1 0 2 3 3 1 2 3 3 3
5 G2 pT3a, N0, Mx 1 1 1 0 1 2 2 2 2
6 G2 pT2, Nx, M1 1 1 2 3 0 1 3 3 2
7 G2 pT1b, Nx, Mx 1 1 1 1 0 2 2 2 2
8 G2 pT2, Nx, Mx 0 1 3 2 0 1 2 2 2
9 G2 pT3a, Nx, Mx 1 2 1 2 1 2 2 3 2
10 G2 pT3b, Nx, Mx 1 1 1. 2 1 1 2 2 2
11 G2-3 pT3b, Nx, Mx 1 1 0 2 0 1 Degraded RNA
12 G2-3 pT3b, Nx, Mx 1 1 2 2 0 2 2 2 2
13 G2-3 pT2, Nx, Mx 0 2 2 2 0 1 3 3 2
14 G3 pT3b, Nx, M1 1 1 2 2 2 1 3 3 2
15 G3 pT3b, Nx, Mx 1 1 3 3 1 2 2 3 2
16 G2 pT1b, Nx, Mx 0 2 2 2 1 2 2 3 2
17 pT3b, Nx, M1 1 1 1 2 0 1 3 2 3
Non-ccRCC Tumor 
type
pTNM Tumor cells Stromal cells RNA
Macrophages Vessels
GRP GRP GRP-R GRP GRP-R GRP GRP-R GRP GRP-R PBGD
Case
18 pap pT2, Nx, Mx 2 1 0 1 0 1 3 2 3
19 chr pT3b, N2, M1 0 2 3 3 2 3 2 3 2
20 sarc pT4, Nx, Mx 1 1 2 3 0 1 2 2 2
21 sarc pT3a, N2, Mx 1 2 3 3 0 2 2 2 3
22 sarc pT2, N0, Mx 0 3 2 2 0 1 3 3 2
23 sarc pT3a, N2, M1 0 1 3 3 0 1 3 2 3
24 sarc pT3a, Nx, M1 2 2 2 3 0 1 0 1 1
25 db pT3b, N2, Mx 1 3 3 2 0 2 0 2 3
26 db pT3a, Nx, Mx 0 2 1 2 2 2 2 3 2123
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mRNA expression analysis of GRP and GRP receptor 
in ccRCC
mRNA expression analysis of GRP and GRP receptor was
performed in serial sections of the same tissue blocks used
for immunohistochemistry. Particularly for GRP, we could
demonstrate that GRP is synthesised within the tumor envi-
ronment of ccRCC and non-ccRCC (Fig. 1; Table 1).
Immunohistochemical localization of GRP and GRP 
receptor in ccRCC
In ccRCC tumor cells with a low GRP signal were observed
in 12 cases. The mean GRP scores in tumor cells (scoremean
0.71) and tumor vessels (scoremean 0.59) were signiWcantly
lower than in TAM (scoremean 1.65) (P < 0.01). Therefore,
TAM were the main source of GRP in ccRCC.
Addressing the question which cell types express GRP
receptor, a low to high signal intensity was detected in
ccRCC. The mean GRP receptor expression was signiW-
cantly lower in tumor epithelia (scoremean 1.35) than in
TAM (scoremean 1.94) (P < 0.0.5) and lower in association
with tumor microvessels (scoremean 1.58).
In non-ccRCC, a low GRP signal of tumor cells was
detected in three cases and an intermediate signal in two
cases. The mean GRP scores in non-ccRCC tumor cells
(scoremean 0.78) and tumor vessels (scoremean 0.44) were
signiWcantly lower than in TAM (scoremean 2.11) (P < 0.05).
For GRP-R expression, non-ccRCC exhibited the same
pattern as ccRCC, but no signiWcant diVerence was detected
(data not shown).
When comparing immunohistochemically stained serial
sections, we also found GRP and GRP receptor-positive
macrophages and GRP receptor-positive tumor cells
located in close vicinity (Fig. 2).
To conWrm this, we performed double immunoXuores-
cence staining with CD 68 and GRP antibodies macro-
phages within RCC expressed both proteins on their surface
as demonstrated by the orange composite signaling in con-
focal microscopy (Fig. 2).
Comparative analyses of the degree of diVerentiation,
and the tumor stage did not reveal any correlation. The data
on all patients are summarized in Table 1.
Analysis of tumor-free tissues of nine cases revealed a
strong GRP and GRP-R expression in tubules and collect-
ing ducts in contrast to peritubular capillaries where no
expression could be found. No GRP or GRP receptor-posi-
tive macrophages were found in tumor-free tissue.
Discussion
The present study provides evidence that GRP and its high-
aYnity receptor are simultaneously expressed in renal
carcinomas. The staining pattern of tumor cells and micro-
vascular endothelia conWrmed our previous results on the
Table 2 Used primers in PCR
Gene Sequence (5–3) Tm (°C) Product 
length (bp)
GRP
fw tgggcggtggggcactta 64 286
rv tcagctgggggttccttcct
GRP-R
fw ctccccgtgaacgatgactgg 61 389
rv atcttcatcagggcatgggag
PBGD
fw tgtctggtaacggcaatgcggctgcaac 72 127
rv tcaatgttgccaccacactgtccgtct
Fig. 1 Gel electrophoresis of 
RT-PCR products of typical 
cases separated on a 1.5% 
agarose gel. Blots have been 
resorted into groups of ccRCC 
and non-ccRCC. A summary of 
the cases is shown in Table 1123
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of GRP and GRP receptor of 
case 15 (ccRCC a, b), 
19 (chromophobe RCC c, d) and 
case 18 (papillary RCC e, f) 
(£400). GRP expression is 
shown in a, c, and e. GRP-R 
expression is demonstrated in b, 
d, and f. In case 15 (ccRCC), 
GRP and GRP-R are expressed 
by tumor cells, microvessels 
(right arrow), and with highest 
intensity by interstitial macro-
phages (Wlled triangle) which is 
highlighted in the Wgure inlets 
(a, b). In case 19 (chromophobe 
RCC) GRP is expressed by 
foamy (asterisk) and 
perivascular (Wlled triangle) 
macrophages, microvessels 
(right arrow), but not by tumor 
cells. Endothelial GRP 
expression is highlighted in the 
Wgure inlet (a). In case 19, 
GRP-R is expressed by foamy 
(asterisk) and perivascular 
(Wlled triangle) macrophages, 
microvessels (right arrow), and 
with faint signals by tumor cells 
(b). In case 18, GRP is expressed 
by tumor cells, but not by foamy 
macrophages (X) (c). GRP-R 
signals are only faintly seen in 
macrophages (X) and tumor cells 
(d). For detailed description see 
Table 1. g–i Double immunoXu-
orescence staining of GRP and 
CD68 in a papillary renal 
carcinoma, case 18 (£400). 
CD68-positive interstitial 
macrophages are shown in 
g (red Xuorescence). GRP 
signals are demonstrated in 
h (green Xuorescence). Overlay 
of g and h conWnes that 
interstitial macrophages express 
GRP (i)123
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study, we used HOPE Wxation, which allowed the simulta-
neous detection of speciWc mRNA transcripts and of pro-
teins by means of RT-PCR and immunohistochemistry in
17 ccRCC and 9 non-ccRCC.
In most cases, we found a co-expression of mRNA and
protein. Only in cases with RNA degradation and hypoxic
necrosis diVerences between mRNA and protein expression
were observed. Protein expression was located nearby or
within the necrotic rims. The absence of mRNA expression
for GRP can be explained by an advanced degradation of
mRNA, even in cases with detectable PBGD mRNA which
is abundantly expressed in renal carcinomas.
Immunohistochemical analysis of the GRP receptor
expression has been described previously. Detection of the
ligand using a polyclonal GRP antiserum has also been
reported [23, 24]. We found cytoplasmatic signals for GRP,
particularly in TAM and in lower intensity in tumor epithe-
lia. Endothelial expression was found at low levels in few
cases, predominately in ccRCC. GRP receptor expression
analysis was positive, particularly in TAM and microvessels
and with lower intensity in tumor cells of all cases. The dis-
continuous and granular staining for the GRP receptor was
in contrast to the study of Scott et al. [25] who found a more
homogeneous cytoplasmatic staining for the GRP receptor
in carcinoid tumor epithelia, whereas the staining pattern for
GRP corresponded well to our data. GRP and GRP expres-
sion has been analyzed in a broad number of neoplasias.
Up til now, investigators did not pay attention on the
expression of GRP and GRP-R on macrophages and micro-
vessels. The expression of bombesin/GRP in immune cells
has been identiWed in circulating peripheral monocytes and in
alveolar macrophages [26]. Furthermore, GRP acts as chemo-
attractant for murine peritoneal macrophages [20] and poten-
tially stimulates cytotoxic natural killer cells both in vivo and
in vitro [27]. In contrast, Meloni et al. [26] showed that bom-
besin/GRP stimulates the release of interleukin-8 (IL-8) by
peripheral monocytes and may thereby promote neoangio-
genesis and tumor growth indirectly. In renal carcinomas, a
high number of inWltrating monocytes and macrophages have
already been identiWed [28]. The stimulation of the GRP-R
induced the release of interleukin-8 and vascular endothelial
growth factor in human prostate cancer cell lines [29].
The detection of the GRP-R on tumor microvessels
underlines the importance of GRP for the progression of
renal carcinomas and suggests the presence of an autocrine
or paracrine loop within the tumor. We have shown previ-
ously that the density of perfused microvessels and tumor
blood Xow are reduced if a speciWc GRP receptor antago-
nist is administered into nude mice bearing subcutaneously
implanted renal carcinomas [12]. However, our Wnding has
been questioned by Busby et al. [30] who demonstrated that
bombesin/GRP did not have any mitogenic eVect on iso-
lated human vascular endothelial cells (HUVEC). This dis-
crepancy may be explained by the fact that HUVEC
originate from the umbilical cord and the Wndings that we
have also identiWed GRP receptors on tumor pericytes that
may also be involved in the proliferation of endothelia.
In conclusion, our study conWrms the presence of both
GRP and GRP receptor in ccRCC. TAM are the main
source of intratumoral GRP. The results suggest a para-
crine/autocrine signaling within renal carcinomas between
TAM, tumor epithelia and microvessels; whereas, the func-
tional relevance of GRP receptors in microvessels and
tumor epithelia has been investigated, the signiWcance and
the function of the GRP receptor expression in macro-
phages needs further elucidation.
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